Andrew Advani

MD, FRCP, PhD, MBChB(Hons), BSc

Scientist

Biography

Dr. Andrew Advani is a Staff Endocrinologist and Associate Professor/Clinician Scientist at the Keenan Research Centre for Biomedical Science, St. Michael’s Hospital and Department of Medicine at University  of Toronto. His research program is focused on the discovery and development of new treatments for diabetic kidney disease and related cardiovascular and kidney diseases. Dr. Advani holds the Keenan Chair in Medicine at St. Michael’s Hospital and University of Toronto.

Despite current treatments, people with diabetes continue to be affected by the long-term consequences of the disease. These long-term consequences include kidney disease, eye disease, nerve disease and heart disease. Kidney disease due to diabetes is the most common cause of kidney failure requiring treatment with dialysis or a kidney transplant and people with kidney disease are much more likely to die from heart disease. The Advani Lab is committed to conducting research on the causes of kidney disease in diabetes and on the links between kidney disease and heart disease. Through this research, Dr. Advani aims to develop new and better treatments for diabetes to reduce the burden of the condition on the millions of people affected.

Dr. Advani completed his medical training at the University of Edinburgh (UK) in 1996 and his PhD at Newcastle University (UK) in 2003. He was appointed on Staff at St. Michael’s Hospital in 2008. He is a Fellow of the Royal College of Physicians (UK). He has over 90 publications and has won awards from the British Hypertension Society, Royal College of Physicians (UK), Diabetes Canada, Canadian Society of Endocrinology and Metabolism and Banting and Best Diabetes Centre.

In his clinical practice, Dr. Advani provides care for people living with diabetes, especially young adults living with Type 1 diabetes. Through this work, Dr. Advani’s research program is also examining innovative ways for improving the lives of young people living with diabetes.

The Advani Lab is always interested in hearing from highly motivated and accomplished individuals interested in post-doctoral fellowships or graduate studentships.

Recent Publications

  1. Kugathasan, L, Sridhar, VS, Tommerdahl, KL, Xu, C, Bjornstad, P, Advani, A et al.. Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes. Metabolism. 2024;153 :155785. doi: 10.1016/j.metabol.2024.155785. PubMed PMID:38215965 .
  2. Sourris, KC, Ding, Y, Maxwell, SS, Al-Sharea, A, Kantharidis, P, Mohan, M et al.. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 2024;105 (1):132-149. doi: 10.1016/j.kint.2023.09.029. PubMed PMID:38069998 .
  3. Hong, LYQ, Yeung, ESH, Tran, DT, Yerra, VG, Kaur, H, Kabir, MDG et al.. Altered expression, but small contribution, of the histone demethylase KDM6A in obstructive uropathy in mice. Dis Model Mech. 2023;16 (9):. doi: 10.1242/dmm.049991. PubMed PMID:37655466 PubMed Central PMC10482012.
  4. Vaswani, CM, Varkouhi, AK, Gupta, S, Ektesabi, AM, Tsoporis, JN, Yousef, S et al.. Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury. Mol Ther. 2023;31 (9):2681-2701. doi: 10.1016/j.ymthe.2023.06.011. PubMed PMID:37340634 PubMed Central PMC10491994.
  5. Yerra, VG, Batchu, SN, Kaur, H, Kabir, MDG, Liu, Y, Advani, SL et al.. Pressure overload induces ISG15 to facilitate adverse ventricular remodeling and promote heart failure. J Clin Invest. 2023;133 (9):. doi: 10.1172/JCI161453. PubMed PMID:37115698 PubMed Central PMC10145941.
  6. Kaur, H, Yerra, VG, Batchu, SN, Tran, DT, Kabir, MDG, Liu, Y et al.. Single cell G-protein coupled receptor profiling of activated kidney fibroblasts expressing transcription factor 21. Br J Pharmacol. 2023;180 (22):2898-2915. doi: 10.1111/bph.16101. PubMed PMID:37115600 .
  7. Kugathasan, L, Dubrofsky, L, Advani, A, Cherney, DZI. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. Expert Rev Cardiovasc Ther. 2023;21 (1):15-34. doi: 10.1080/14779072.2023.2159810. PubMed PMID:36524239 .
  8. Swaich, H, Advani, A. Sustained Improvement in Glycemic Control in Emerging Adults with Type 1 Diabetes 2 Years After the Start of the COVID-19 Pandemic. Diabetes Ther. 2023;14 (1):153-165. doi: 10.1007/s13300-022-01346-5. PubMed PMID:36467396 PubMed Central PMC9708124.
  9. Connelly, KA, Wu, E, Visram, A, Friedberg, MK, Batchu, SN, Yerra, VG et al.. The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding. Cardiovasc Drugs Ther. 2024;38 (1):57-68. doi: 10.1007/s10557-022-07377-1. PubMed PMID:36173474 .
  10. Gupta, S, Amatullah, H, Tsoporis, JN, Wei, K, Monteiro, APT, Ektesabi, AM et al.. DJ-1 binds to Rubicon to Impair LC-3 Associated Phagocytosis. Cell Death Differ. 2022;29 (10):2024-2033. doi: 10.1038/s41418-022-00993-2. PubMed PMID:35641782 PubMed Central PMC9525254.
Search PubMed

Affiliations & Other Activities

  • Staff Endocrinologist/Clinician Scientist, Division of Endocrinology, St. Michael’s Hospital
  • Associate Professor/Clinician Scientist, Department of Medicine, University of Toronto